Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Nat Commun ; 9(1): 4976, 2018 11 26.
Article in English | MEDLINE | ID: mdl-30478310

ABSTRACT

Intrinsic apoptosis is critical to prevent tumor formation and is engaged by many anti-cancer agents to eliminate tumor cells. BAX and BAK, the two essential mediators of apoptosis, are thought to be regulated through similar mechanisms and act redundantly to drive apoptotic cell death. From an unbiased genome-wide CRISPR/Cas9 screen, we identified VDAC2 (voltage-dependent anion channel 2) as important for BAX, but not BAK, to function. Genetic deletion of VDAC2 abrogated the association of BAX and BAK with mitochondrial complexes containing VDAC1, VDAC2, and VDAC3, but only inhibited BAX apoptotic function. Deleting VDAC2 phenocopied the loss of BAX in impairing both the killing of tumor cells by anti-cancer agents and the ability to suppress tumor formation. Together, our studies show that efficient BAX-mediated apoptosis depends on VDAC2, and reveal a striking difference in how BAX and BAK are functionally impacted by their interactions with VDAC2.


Subject(s)
Apoptosis , Carcinogenesis/metabolism , Carcinogenesis/pathology , Voltage-Dependent Anion Channel 2/metabolism , bcl-2-Associated X Protein/metabolism , Animals , CRISPR-Cas Systems/genetics , Embryonic Development , HCT116 Cells , HeLa Cells , Humans , Mice, Inbred C57BL , Mitochondria/metabolism , Promoter Regions, Genetic/genetics , bcl-2 Homologous Antagonist-Killer Protein/metabolism
2.
Mol Cancer Ther ; 2(8): 729-37, 2003 Aug.
Article in English | MEDLINE | ID: mdl-12939462

ABSTRACT

Antigens and receptors that are highly expressed on tumor stromal cells, such as fibroblast activation protein (FAP), are attractive targets for antibody-based therapies because the supporting stroma and vessel network is essential for a solid neoplasm to grow beyond a size of 1-2 mm. The in vivo characterization of antibodies targeting human stromal or vessel antigens is hindered by the lack of an appropriate mouse model system because xenografts in standard mouse models express stromal and vessels elements of murine origin. This limitation may be overcome by the development of a human skin/mouse chimeric model, which is established by transplanting human foreskin on to the lateral flank of severe combined immunodeficient mice. The subsequent inoculation of breast carcinoma MCF-7 cells within the dermis of the transplanted human skin resulted in the production of xenografts expressing stromal and vessel elements of human origin. Widespread expression of human FAP-positive reactive stromal fibroblasts within xenografts was seen up to 2 months posttransplantation and postinjection of cells. Human blood vessel antigen expression also persisted at 2 months posttransplantation and postinjection of cells with murine vessels coexisting with the human vascular supply. The model was subsequently used to evaluate the biodistribution properties of an iodine-131-labeled humanized anti-FAP monoclonal antibody (BIBH-7). The results showed high specific targeting of the stromal compartment of the xenograft, indicating that the model provides a useful and novel approach for the in vivo assessment of the immunotherapeutic potential of molecules targeting human stroma and angiogenic systems.


Subject(s)
Antigens, Neoplasm/analysis , Antigens, Neoplasm/metabolism , Biomarkers, Tumor/analysis , Mice, SCID , Serine Endopeptidases/analysis , Animals , Antibodies, Monoclonal , Breast Neoplasms , Cell Line, Tumor , Endopeptidases , Gelatinases , Gene Targeting , H-2 Antigens/metabolism , HLA-A Antigens/analysis , HLA-B Antigens/analysis , HLA-C Antigens/analysis , HLA-C Antigens/metabolism , Humans , Membrane Proteins , Mice , Models, Animal , Neoplasm Transplantation , Skin/chemistry , Skin Transplantation , Stromal Cells/enzymology , Transplantation, Heterologous
3.
Int J Cancer ; 98(3): 398-408, 2002 Mar 20.
Article in English | MEDLINE | ID: mdl-11920591

ABSTRACT

In some respects, the EGFR appears to be an attractive target for tumor-targeted antibody therapy: it is overexpressed in many types of epithelial tumor and inhibition of signaling often induces an anti-tumor effect. The use of EGFR specific antibodies, however, may be limited by uptake in organs that have high endogenous levels of the wild type EGFR such as the liver. The de2-7 EGFR (or EGFRvIII) is a naturally occurring extracellular truncation of the EGFR found in a number of tumor types including glioma, breast, lung and prostate. Antibodies directed to this tumor specific variant of the EGFR provide an alternative targeting strategy, although the lower proportion of tumors that express the de2-7 EGFR restricts this approach. We describe a novel monoclonal antibody (MAb 806) that potentially overcomes the difficulties associated with targeting the EGFR expressed on the surface of tumor cells. MAb 806 bound to de2-7 EGFR transfected U87MG glioma cells (U87MG.Delta 2-7) with high affinity (approximately 1 x 10(9) M(-1)), but did not bind parental cells that express the wild type EGFR. Consistent with this observation, MAb 806 was unable to bind a soluble version of the wild type EGFR containing the extracellular domain. In contrast, immobilization of this extracellular domain to ELISA plates induced saturating and dose response binding of MAb 806, suggesting that MAb 806 can bind the wild type EGFR under certain conditions. MAb 806 also bound to the surface of A431 cells, which due to an amplification of the EGFR gene express large amounts of the EGFR. Interestingly, MAb 806 only recognized 10% of the total EGFR molecules expressed by A431 cells and the binding affinity was lower than that determined for the de2-7 EGFR. MAb 806 specifically targeted U87MG.Delta 2-7 and A431 xenografts grown in nude mice with peak levels in U87MG.Delta 2-7 xenografts detected 8 h after injection. No specific targeting of parental U87MG xenografts was observed. Following binding to U87MG.Delta 2-7 cells, MAb 806 was rapidly internalized by macropinocytosis and subsequently transported to lysosomes, a process that probably contributes to the early targeting peak observed in the xenografts. Thus, MAb 806 can be used to target tumor cells containing amplification of the EGFR gene or de2-7 EGFR but does not bind to the wild type EGFR when expressed on the cell surface.


Subject(s)
Antibodies, Monoclonal/immunology , Antineoplastic Agents/pharmacology , Brain Neoplasms/genetics , ErbB Receptors/genetics , ErbB Receptors/immunology , Glioma/genetics , Animals , Antibody Specificity , Brain Neoplasms/immunology , Enzyme-Linked Immunosorbent Assay , Gene Expression Regulation, Neoplastic , Glioma/immunology , Humans , Mice , Mice, Inbred BALB C , Mice, Nude , Microscopy, Electron , Precipitin Tests , Protein Binding , Transfection , Transplantation, Heterologous , Treatment Outcome , Tumor Cells, Cultured
SELECTION OF CITATIONS
SEARCH DETAIL
...